Stock Scorecard
Stock Summary for Bluebird bio Inc (BLUE) - $0.95 as of 4/18/2024 8:56:36 PM EST
Total Score
11 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BLUE
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BLUE
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BLUE
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for BLUE
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for BLUE
Financial Details for BLUE
Company Overview |
|
|---|---|
| Ticker | BLUE |
| Company Name | Bluebird bio Inc |
| Country | USA |
| Description | bluebird bio, Inc., a biotechnology company, researches, develops and markets transformative gene therapies for serious genetic diseases and cancer. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2023 |
| Next Earnings Date | 5/7/2024 |
Stock Price History |
|
| Last Day Price | 0.95 |
| Last Day Price Updated | 4/18/2024 8:56:36 PM EST |
| Last Day Volume | 6,530,709 |
| Average Daily Volume | 7,004,110 |
| 52-Week High | 5.53 |
| 52-Week Low | 0.88 |
| Last Price to 52 Week Low | 7.95% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 61.37 |
| Sector PE | 61.34 |
| 5-Year Average PE | -1.27 |
| Free Cash Flow Ratio | 1.06 |
| Industry Free Cash Flow Ratio | 18.52 |
| Sector Free Cash Flow Ratio | 30.17 |
| Current Ratio Most Recent Quarter | 1.55 |
| Total Cash Per Share | 0.90 |
| Book Value Per Share Most Recent Quarter | 2.08 |
| Price to Book Ratio | 0.96 |
| Industry Price to Book Ratio | 7.52 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 9.76 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.88 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
| Total Shares Outstanding | 192,742,000 |
| Market Capitalization | 183,104,900 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 67.47% |
| Reported EPS 12 Trailing Months | -0.63 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -1.12 |
| Net Income Twelve Trailing Months | -91,167,000 |
| Net Income Past Year | -266,578,000 |
| Net Income Prior Year | -819,378,000 |
| Quarterly Revenue Growth YOY | 17,353.00% |
| 5-Year Revenue Growth | -57.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 174,293,000 |
| Total Cash Past Year | 180,327,000 |
| Total Cash Prior Year | 303,194,000 |
| Net Cash Position Most Recent Quarter | 174,293,000 |
| Net Cash Position Past Year | 180,327,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 196,343,000 |
| Total Stockholder Equity Prior Year | 374,277,000 |
| Total Stockholder Equity Most Recent Quarter | 222,536,000 |
Options |
|
| Put/Call Ratio | 0.21 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.09 |
| MACD Signal | -0.06 |
| 20-Day Bollinger Lower Band | 0.29 |
| 20-Day Bollinger Middle Band | 1.44 |
| 20-Day Bollinger Upper Band | 2.59 |
| Beta | 0.80 |
| RSI | 33.63 |
| 50-Day SMA | 2.75 |
| 200-Day SMA | 12.28 |
System |
|
| Modified | 4/18/2024 7:33:01 PM EST |